论文部分内容阅读
目的:系统评价奥扎格雷钠联合灯盏花素注射液治疗急性脑梗死的临床疗效与安全性。方法:检索国内外多个数据库中公开发表的关于奥扎格雷钠联合灯盏花素治疗急性脑梗死的临床随机对照试验的相关文献,依据纳入、排除标准筛选文献应用Review Manager5.3进行Meta分析。结果:共纳入19个随机对照试验,分析显示,奥扎格雷钠联合灯盏花素注射液治疗急性脑梗死的神经功能缺损临床疗效的比值比(OR)合并值为4.46(95%可信区间为3.16~5.64)。神经功能缺损评分疗效加权均数差(WMD)合并值为-4.79(95%可信区间为-5.47~-4.12)。结论:奥扎格雷钠联合灯盏花素注射液治疗急性脑梗死有一定疗效,且安全、不良反应较少,但由于所选样本质量偏低,尚需进一步进行严格的,多中心的随机双盲对照试验来验证。
Objective: To systematically evaluate the clinical efficacy and safety of sodium ozagrel combined with breviscapine injection in the treatment of acute cerebral infarction. Methods: The related literatures about randomized controlled trials of ozagrel combined with Breviscapine on acute cerebral infarction were searched and published in domestic and foreign databases. According to the included and excluded standard screening literature, Meta-analysis was performed with Review Manager 5.3. RESULTS: A total of 19 randomized controlled trials were conducted. The analysis showed that the odds ratio (OR) of combined treatment with ozagrel sodium and breviscapine in the treatment of acute neurological deficits was 4.46 (95% confidence interval 3.16 ~ 5.64). The mean value of the WMD for the neurological deficit score was -4.79 (95% confidence interval -5.47-4.12). Conclusion: Ozagrel sodium combined with breviscapine injection has some curative effect in the treatment of acute cerebral infarction with safe and less adverse reactions. However, due to the low quality of selected samples, a rigorous and multicenter randomized double blind Control test to verify.